13.93

1.00% -0.14

After Hours: 13.81 -0.12 -0.86%

Biohaven Ltd (BHVN)

Overview News Price History Option Chain Financials Why BHVN Down? Discussions Forecast

Biohaven Ltd stock is traded at $13.93, with a volume of 1.87M. It is down -1.00% in the last 24 hours and up +3.41% over the past month. Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Previous Close:

$14.07

Open:

$14.1

24h Volume:

1.87M

Relative Volume:

0.94

Market Cap:

$1.47B

Revenue:

Net Income/Loss:

$-766.97M

P/E Ratio:

-1.8185

EPS:

-7.66

Net Cash Flow:

$-646.43M

1W Performance:

-12.22%

1M Performance:

+3.41%

6M Performance:

-52.64%

1Y Performance:

-61.03%

1-Day Range:

$13.63

$14.15

1-Week Range:

$13.63

$15.55

52-Week Range:

$12.79

$55.70

Biohaven Ltd Stock (BHVN) Company Profile

Name

Biohaven Ltd

Sector

Healthcare (1152)

Industry

Biotechnology (648)

Phone

203-404-0410

Address

215 CHURCH STREET, NEW HAVEN, CT

Employee

256

Twitter

@biohavenpharma

Next Earnings Date

2025-08-08

Latest SEC Filings

BHVN's Discussions on Twitter

Compare BHVN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BHVN Biohaven Ltd	13.93	1.48B	0	-766.97M	-646.43M	-7.66
VRTX Vertex Pharmaceuticals Inc	394.53	99.62B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	465.89	61.52B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	560.00	58.91B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	756.38	46.69B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	324.34	34.54B	3.81B	-644.79M	-669.77M	-6.24

Biohaven Ltd Stock (BHVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-03-25	Initiated	Raymond James	Strong Buy
May-19-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Feb-11-25	Initiated	Deutsche Bank	Buy
Sep-16-24	Initiated	Jefferies	Buy
Sep-04-24	Initiated	Bernstein	Outperform
Jul-24-24	Initiated	Morgan Stanley	Overweight
Feb-16-24	Initiated	RBC Capital Mkts	Outperform
Feb-06-24	Initiated	UBS	Buy
Dec-22-23	Initiated	H.C. Wainwright	Buy
Dec-08-23	Initiated	Robert W. Baird	Outperform
Jan-24-23	Initiated	SVB Securities	Outperform
Jan-04-23	Initiated	JP Morgan	Overweight
Dec-02-22	Initiated	BTIG Research	Buy
Oct-26-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Oct-12-22	Initiated	Piper Sandler	Overweight
Aug-19-22	Downgrade	Piper Sandler	Overweight → Neutral
Aug-08-22	Downgrade	Wedbush	Outperform → Neutral
May-11-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-19-21	Resumed	Morgan Stanley	Equal-Weight
Aug-10-21	Downgrade	UBS	Buy → Neutral
Aug-03-21	Reiterated	Canaccord Genuity	Buy
Mar-11-21	Initiated	UBS	Buy
Dec-15-20	Initiated	H.C. Wainwright	Buy
Apr-17-20	Initiated	Cowen	Outperform
Feb-10-20	Downgrade	Oppenheimer	Outperform → Perform
Feb-06-20	Initiated	Mizuho	Buy
Nov-22-19	Initiated	Wedbush	Outperform
Jun-25-19	Reiterated	Canaccord Genuity	Buy
May-06-19	Initiated	Goldman	Buy
Apr-09-19	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-04-19	Reiterated	Needham	Buy
Jul-03-18	Reiterated	Needham	Buy
Jul-02-18	Reiterated	Needham	Buy
Apr-05-18	Downgrade	Barclays	Overweight → Equal Weight
Feb-22-18	Reiterated	Canaccord Genuity	Buy
Dec-15-17	Initiated	Canaccord Genuity	Buy
Oct-03-17	Reiterated	Needham	Buy

View All

Biohaven Ltd Stock (BHVN) Latest News

Sep 12, 2025

BHVN FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Biohaven Ltd. Investors to Secure Counsel Before Important September 12 Deadline in Securities Class Action – BHVN - GlobeNewswire Inc.

Sep 12, 2025

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven - GlobeNewswire

Sep 12, 2025